You are here: Home » News-CM » Companies » News
Business Standard

Zydus Cadila receives final approval for Acyclovir for Injection USP

Capital Market 

From USFDA

Zydus Cadila has received the final approval from the USFDA to market Acyclovir for Injection USP in strengths of 500 mg/vial and 100 mg/vial.

Acyclovir for Injection USP which caters to anti-viral segment, will be produced at the group's formulations manufacturing facility at Moraiya, Ahmedabad.

Powered by Capital Market - Live News

(This story has not been edited by Business Standard staff and is auto-generated from a syndicated feed.)

RECOMMENDED FOR YOU